You are here: Industry Insights > EpiPen

News List

FDA Reports EpiPen Auto-Injector Errors due to Malfunctions americanpharmaceuticalreview
March 30, 2020
The U.S. Food and Drug Administration (FDA) is alerting patients, caregivers and health care professionals that EpiPen 0.3mg and EpiPen Jr 0.15mg auto-injectors ...
US researchers develop ‘EpiPen’ to treat injured spinal cords pharmaceutical-technology
July 17, 2019
Researchers at the University of Michigan in the US have developed a nanoparticles injection to prevent the immune system from overreacting to trauma in order to potentially prevent paralysis from certain spinal cord injuries.
Michigan scientists develop EpiPen to heal spinal cord injuries biospectrumasia
July 16, 2019
An injection of nanoparticles can prevent the body’s immune system from overreacting to trauma, potentially preventing some spinal cord injuries from resulting in paralysis.
Teva’s generic EpiPen launch stalls months after approval biospectrumasia
February 02, 2019
The short supply represents a missed opportunity for Teva to compete with Mylan in a roughly $750 million a year US market
Teva prices generic EpiPen at parity with Mylan's generic version firstwordpharma
November 28, 2018
Teva said Tuesday that its generic version of Mylan's EpiPen (epinephrine) will carry a wholesale acquisition cost of $300 in the US. The Israeli drugmaker's product gained FDA approval in August as the first generic version of the auto-injector for the e
FDA Alerts Some EpiPen Auto-Injectors May Not Readily Slide Out of Tube americanpharmaceuticalreview
November 07, 2018
FDA Alerts Some EpiPen Auto-Injectors May Not Readily Slide Out of Tube
FDA says there is shortage of Mylan’s Epipen in US biospectrumasia
May 11, 2018
in Share .    Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment
US FDA warns of problems with EpiPen manufacturing plant expressbpd
September 11, 2017
Tens of thousands of EpiPens, sold by Mylan NV, were recalled worldwide in March following two reports of the life-saving allergy shot failing to work in emergencies
FDA approves Adamis’ cheaper rival to EpiPen pharmaphorum
June 19, 2017
Mylan is faced with a new rival to its allergic reaction shot, EpiPen (epinephrine), after the FDA approved a generic from San Diego’s Adamis Pharmaceuticals.